Biases affecting injected doses of an experimental drug during clinical trials

• Published in: Current controlled trials in cardiovascular medicine Vol. 17; no. 1; p. 321
• Main Authors: Perrottet, Nancy, Brunner-Ferber, Françoise, Grouzmann, Eric, Spertini, François, Biollaz, Jérôme, Buclin, Thierry, Widmer, Nicolas
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 16.07.2016; BioMed Central
• Subjects: Adsorption; Albumins - metabolism; Analysis; Bias; Biological Availability; Biological products; Biological response modifiers; Biosimilar Pharmaceuticals - administration & dosage; Biosimilar Pharmaceuticals - chemistry; Biosimilar Pharmaceuticals - pharmacokinetics; Clinical trials; Clinical Trials, Phase I as Topic - methods; Density; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Compounding; Drug Dosage Calculations; Drug dosages; Drug Labeling; Enzyme-linked immunosorbent assay; Experiments; Health aspects; Humans; Injections, Intravenous; Injections, Subcutaneous; Interferon; Interferon beta; Interferon beta-1a - administration & dosage; Interferon beta-1a - chemistry; Interferon beta-1a - pharmacokinetics; Peptides; Pharmaceuticals; Pharmacodynamics; Pharmacokinetics; Protein Binding; Randomized Controlled Trials as Topic - methods; Research Design; Viral antigens; United States; Switzerland; Germany; Clinical trials; Drug dose; Pharmacokinetics; Drug evaluation; Bias; Phase I as topic
• ISSN: 1745-6215; 1745-6215
• DOI: 10.1186/s13063-016-1463-5

During clinical trials, researchers rarely question nominal doses specified on labels of investigational products, overlooking the potential for inaccuracies that may result when calculating pharmacokinetic and pharmacodynamic parameters. This study evaluated the disparity between nominal doses and the doses actually administered in two Phase I trials of a biosimilar drug. In Trial A, 12 healthy volunteers received various doses of an interferon β-1a biosimilar via either subcutaneous or intravenous injection, prepared by partially emptying 0.53 ml syringes supplied by the manufacturer. In Trial B, 12 volunteers received three different formulations of the drug via intravenous injection (biosimilar with and without albumin and a comparator), followed by multiple subcutaneous injections. In both trials, the dose administered was calculated as D = C × V - losses, where C is the drug concentration assessed using ELISA, V is the volume administered calculated using syringe weighing and losses are deduced from in-vitro experiments. Interferon binding to added albumin and infusion lines was evaluated using a (125)I-interferon tracer with gel-filtration chromatography. In Trial A, measured concentrations were close to the nominal strength indicated by the manufacturer (median bias: -6 %), whereas in Trial B they differed significantly for all three formulations (median biases: +67 %, +73 % and +31 % for the biosimilar with albumin, the biosimilar without albumin and the comparator, respectively). In Trial A, the doses actually administered showed large variability and biases, especially at the lowest doses. Indeed, actually injected volumes differed by as much as 74 % from theoretical volumes - a phenomenon mainly attributed to unnoticed fluid re-aspiration through the syringe needle. This was corrected in Trial B. Interferon was not significantly adsorbed on the infusion lines used for intravenous administration. Its binding to albumin was slow, reaching 50 % after a 16 h incubation. These examples illustrate the importance of assessing the actual doses administered in clinical trials, to ensure accuracy in the determination of clearance, distribution volume, bioavailability and dose-response relationships. Clinicaltrials.gov NCT02515695 (Trial A) and NCT02517788 (Trial B). Registered on 24 July and 5 August 2015, respectively.